Nonclinical Testing Terminology
2026-19350 | Food and Drug Administration | Final rule | Sep 22 |
Nonclinical Testing Terminology
2026-19349 | Food and Drug Administration | Proposed rule | Sep 22 |
Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program
2026-15652 | Centers for Medicare & Medicaid Services | Final rule | Aug 3 |
Reducing Barriers to Medical Use Licensing
2026-15080 | Nuclear Regulatory Commission | Proposed rule | Jul 27 |
Revocation of the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausages
2026-14910 | Food and Drug Administration | Final rule | Jul 23 |
Proposal To Revoke the Color Additive Listing for Use of Citrus Red No. 2 on the Skins of Mature Oranges
2026-14909 | Food and Drug Administration | Proposed rule | Jul 23 |
Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
2026-14327 | Centers for Medicare & Medicaid Services | Proposed rule | Jul 16 |
Reforming and Modernizing the NRC's Radiation Protection Framework
2026-14208 | Nuclear Regulatory Commission | Proposed rule | Jul 15 |
Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
2026-14073 · significant | Food and Drug Administration | Proposed rule | Jul 13 |
Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies
2026-13602 | Centers for Medicare & Medicaid Services | Proposed rule | Jul 6 |
Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments
2026-10292 · significant | Centers for Medicare & Medicaid Services | Proposed rule | May 22 |
Modification of Certain Terminology in Title 21
2026-08826 | Food and Drug Administration | Proposed rule | May 6 |
Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program
2026-06642 | Centers for Medicare & Medicaid Services | Proposed rule | Apr 6 |
Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction
2026-04797 · significant | Centers for Medicare & Medicaid Services | Final rule | Mar 12 |
Revising the National Drug Code Format and Drug Label Barcode Requirements
2026-04368 | Food and Drug Administration | Final rule | Mar 5 |
Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community
2026-03286 | Food and Drug Administration | Final rule | Feb 19 |
Revocation of Methods of Analysis Regulation
2026-03285 | Food and Drug Administration | Final rule | Feb 19 |
Listing of Color Additives Exempt From Certification; Spirulina Extract
2026-02314 | Food and Drug Administration | Final rule | Feb 6 |
Listing of Color Additives Exempt From Certification; Beetroot Red
2026-02313 | Food and Drug Administration | Final rule | Feb 6 |
Statutory Updates to Branded Prescription Drug Fee Regulations
2025-24153 | Internal Revenue Service | Proposed rule | Jan 2 |
The Sunset Rule
2025-21784 · significant | Nuclear Regulatory Commission | Final rule | Dec 3, 2025 |
Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies
2025-21767 · significant | Centers for Medicare & Medicaid Services | Final rule | Dec 2, 2025 |
Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
2025-19787 · significant | Centers for Medicare & Medicaid Services | Final rule | Nov 5, 2025 |
Listing of Color Additives Exempt From Certification; Gardenia (Genipin) Blue; Confirmation of Effective Date
2025-19166 | Food and Drug Administration | Final rule | Oct 1, 2025 |
Prior Notice: Adding Requirement To Submit Mail Tracking Number for Articles of Food Arriving by International Mail and Timeframe for Post-Refusal and Post-Hold Submissions
2025-18655 | Food and Drug Administration | Final rule | Sep 25, 2025 |
Proposal To Remove the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausages
2025-18023 | Food and Drug Administration | Proposed rule | Sep 17, 2025 |
Advisory Committee; Arthritis Advisory Committee; Termination; Removal From List of Standing Committees
2025-16629 | Food and Drug Administration | Final rule | Aug 29, 2025 |
Listing of Color Additives Exempt From Certification; Calcium Phosphate; Confirmation of Effective Date
2025-16047 | Food and Drug Administration | Final rule | Aug 21, 2025 |
Listing of Color Additives Exempt From Certification; Galdieria Extract Blue; Confirmation of Effective Date
2025-16046 | Food and Drug Administration | Final rule | Aug 21, 2025 |
Listing of Color Additives Exempt From Certification; Butterfly Pea Flower Extract; Confirmation of Effective Date
2025-16045 | Food and Drug Administration | Final rule | Aug 21, 2025 |
Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
2025-13271 · significant | Centers for Medicare & Medicaid Services | Proposed rule | Jul 16, 2025 |
Listing of Color Additives Exempt From Certification; Gardenia (Genipin) Blue
2025-13175 | Food and Drug Administration | Final rule | Jul 15, 2025 |
Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies
2025-12347 · significant | Centers for Medicare & Medicaid Services | Proposed rule | Jul 2, 2025 |
Listing of Color Additives; Myoglobin; Confirmation of Effective Date
2025-09680 | Food and Drug Administration | Final rule | May 29, 2025 |
Listing of Color Additives Exempt From Certification; Galdieria Extract Blue
2025-08250 | Food and Drug Administration | Final rule | May 12, 2025 |
Listing of Color Additives Exempt From Certification; Calcium Phosphate
2025-08249 | Food and Drug Administration | Final rule | May 12, 2025 |
Listing of Color Additives Exempt From Certification; Butterfly Pea Flower Extract
2025-08248 | Food and Drug Administration | Final rule | May 12, 2025 |
Listing of Color Additives Exempt From Certification; Myoglobin
2025-01239 | Food and Drug Administration | Final rule | Jan 17, 2025 |
Special Registrations for Telemedicine and Limited State Telemedicine Registrations
2025-01099 · significant | Drug Enforcement Administration | Proposed rule | Jan 17, 2025 |
Color Additive Petition From Center for Science in the Public Interest, et al.; Request To Revoke Color Additive Listing for Use of FD&C Red No. 3 in Food and Ingested Drugs
2025-00830 | Food and Drug Administration | Final rule | Jan 16, 2025 |
Nonprescription Drug Product With an Additional Condition for Nonprescription Use
2024-30261 · significant | Food and Drug Administration | Final rule | Dec 26, 2024 |
Clinical Trials Registration and Results Information Submission
2024-28475 | Health and Human Services Department | Final rule | Dec 9, 2024 |
Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments
2024-25382 · significant | Centers for Medicare & Medicaid Services | Final rule | Dec 9, 2024 |
Color Additive Certification; Increase in Fees for Certification Services
2024-25974 · significant | Food and Drug Administration | Final rule | Nov 8, 2024 |
Technical Corrections to the TTB Regulations
2024-23662 | Alcohol and Tobacco Tax and Trade Bureau | Final rule | Nov 6, 2024 |
Health and Human Services Adoption of the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards
2024-21984 | Health and Human Services Department | Final rule | Oct 2, 2024 |
Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program
2024-21254 | Centers for Medicare & Medicaid Services | Final rule | Sep 26, 2024 |
Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community
2024-21559 | Food and Drug Administration | Proposed rule | Sep 20, 2024 |
USDA Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards
2024-18544 | Agriculture Department | Final rule | Aug 26, 2024 |
Submission of Food and Drug Administration Import Data in the Automated Commercial Environment for Certain Tobacco Products
2024-18343 | Food and Drug Administration | Proposed rule | Aug 16, 2024 |
Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments
2024-14828 | Centers for Medicare & Medicaid Services | Proposed rule | Jul 31, 2024 |
Advisory Committee; Allergenic Products Advisory Committee; Termination; Removal From List of Standing Committees
2024-15136 | Food and Drug Administration | Final rule | Jul 10, 2024 |
USDA Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards
2024-13845 | Agriculture Department | Proposed rule | Jul 1, 2024 |
21st Century Cures Act: Establishment of Disincentives for Health Care Providers That Have Committed Information Blocking
2024-13793 | Centers for Medicare & Medicaid Services | Final rule | Jul 1, 2024 |
Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases
2024-13190 | Food and Drug Administration | Final rule | Jun 18, 2024 |
Administrative Destruction
2024-11564 | Food and Drug Administration | Final rule | May 31, 2024 |
Advisory Committee; Science Advisory Board to the National Center for Toxicological Research; Termination; Removal From List of Standing Committees
2024-11811 | Food and Drug Administration | Final rule | May 30, 2024 |
Medicaid Program; Ensuring Access to Medicaid Services
2024-08363 · significant | Centers for Medicare & Medicaid Services | Final rule | May 10, 2024 |
340B Drug Pricing Program; Administrative Dispute Resolution Regulation
2024-08262 · significant | Health and Human Services Department | Final rule | Apr 19, 2024 |
Poison Prevention Packaging Requirements; Exemption of Baloxavir Marboxil Tablets in Packages Containing Not More Than 80 mg of the Drug
2024-07651 | Consumer Product Safety Commission | Final rule | Apr 19, 2024 |
Medicaid Program; Streamlining the Medicaid, Children's Health Insurance Program, and Basic Health Program Application, Eligibility Determination, Enrollment, and Renewal Processes
2024-06566 | Centers for Medicare & Medicaid Services | Final rule | Apr 2, 2024 |
Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
2024-05801 | Food and Drug Administration | Proposed rule | Mar 20, 2024 |
Labeling Requirements for Approved or Conditionally Approved New Animal Drugs
2024-04840 | Food and Drug Administration | Proposed rule | Mar 12, 2024 |
Advisory Committee; Genetic Metabolic Diseases Advisory Committee; Addition to List of Standing Committees
2024-04751 | Food and Drug Administration | Final rule | Mar 6, 2024 |
Medicaid Program; Disproportionate Share Hospital Third-Party Payer Rule
2024-03542 | Centers for Medicare & Medicaid Services | Final rule | Feb 23, 2024 |
Advisory Committee; Digital Health Advisory Committee; Addition to List of Standing Committees
2024-03618 | Food and Drug Administration | Final rule | Feb 22, 2024 |
Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Advantage; Medicare and Medicaid Provider and Supplier Enrollment Policies; and Basic Health Program; Corrections
2024-02705 | Centers for Medicare & Medicaid Services | Final rule | Feb 12, 2024 |
Medical Devices; Quality System Regulation Amendments
2024-01709 | Food and Drug Administration | Final rule | Feb 2, 2024 |
Listing of Color Additives Exempt From Certification; Jagua (Genipin-Glycine) Blue; Confirmation of Effective Date
2024-01106 | Food and Drug Administration | Final rule | Jan 23, 2024 |